Regeneron Pharmaceuticals, Inc., and Sanofi announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) compared to placebo in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation. In a joint statement, the two companies said that Dupixent is the first and only biologic to demonstrate a clin...